Primary Cervical Cancer Screening and Triage Using an mRNA Human Papillomavirus Assay and Visual Inspection

Nieves, Lucybeth MD, MPH; Enerson, Christine L. MD; Belinson, Suzanne MPH, PHD; Brainard, Jennifer MD; Chiesa-Vottero, Andres MD; Nagore, Norma MD; Booth, Christine MD; Pérez, Areli Gutierrez MC; Chávez-Avilés, Mauricio N. MC; Belinson, Jerome MD

International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e318280f3bc
Cervical Cancer
Abstract

Objective: Mexican Cervical Cancer Screening Study II (MECCS II) seeks to develop a highly sensitive and highly specific screening program able to be adapted to all socioeconomic levels in Mexico. The objectives of MECCS II are (1) to compare the sensitivity and specificity for cervical intraepithelial neoplasia (CIN) 3 or cancer of self-collected vaginal specimens tested for high-risk types of the human papillomavirus (HR-HPV) by APTIMA with those tested for HR-HPV by Hybrid Capture 2 (HC2); and (2) determine the efficacy of cryotherapy in the treatment of HR-HPV–positive and acetic acid–aided visual inspection (VIA)–positive and -negative women after VIA triage.

Methods: The study was conducted in rural Mexico. Women aged 30 to 50 years, nonpregnant, with no history of hysterectomy or pelvic irradiation and varied histories of screening, participated. A direct endocervical sample was tested for cytology, HC2, and APTIMA assay (AHPV). Subjects positive on any test were recalled for triage VIA, biopsies, and immediate cryotherapy. Tests were compared using McNemar test.

Results: Two thousand forty-nine patients have complete results. Mean age of the patients was 39.2 years; 7.7% presented with ≥atypical squamous cells of uncertain significance (ASCUS), 1.8% ≥low-grade squamous intraepithelial neoplasia, and 0.5% ≥high-grade squamous intraepithelial neoplasia. Two percent of patients had ≥CIN2, and 0.78% had ≥CIN3 (including 2 with invasive disease). The sensitivity of ThinPrep (>ASCUS), HC2, and AHPV for >CIN3 for direct endocervical collection was 87.5%, 100%, and 100%, respectively. The specificity of ThinPrep (>ASCUS), HC2, and AHPV for >CIN3 was 94.1%, 92.2%, and 93.5%, respectively. Specificities of HC2 and AHPV differed significantly. The overall percentage of agreement among HPV assays (HC2 vs APTIMA) is 97%. Four hundred sixty-nine women returned for VIA. Two hundred ninety-one women were treated with cryotherapy.

Conclusions: The specificity of the APTIMA assay along with high sensitivity is an advantage for primary screening. Follow-up evaluation will be important to determine the true impact of potential undertreatment in the screening algorithm. Self-sampling applications are explored.

Author Information

New Hanover Regional Medical Center, Wilmington, NC.

Address correspondence and reprint requests to Lucybeth Nieves, MD, MPH, New Hanover Regional Medical Center, Zimmer Cancer Center, 2131S 17th St., PO Box 9000, Wilmington, NC 28402. E-mail: lucybethnieves@hotmail.com.

The authors declare no conflicts of interest.

Received August 4, 2012

Accepted December 2, 2012

Copyright © 2013 by IGCS and ESGO